{"filings":[{"id":2088556,"accession_number":"0001688757-26-000047","cik":1688757,"company_name":"ESTABLISHMENT LABS HOLDINGS INC.","ticker":"ESTA","form_type":"8-K","filed_at":"2026-08-06T12:04:41+00:00","items":["2.02","9.01"],"status":"ready","headline":"Establishment Labs Q2 revenue $67.5M (+31.7% YoY); raises FY guidance to $269-271M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue of $67.5M, up 31.7% YoY; US sales $24.7M, up 26% from Q1 2026.","Gross margin improved to 70.6% from 68.8% a year ago; operating loss narrowed to $4.3M from $14.1M.","Adjusted EBITDA turned positive at $3.7M vs a loss of $8.5M in Q2 2025.","Net loss improved to $11.7M from $16.6M; cash balance $71.2M, up $16.5M YoY.","Full-year revenue guidance raised to $269-271M from prior $266.5-268.5M."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2113690694.5902975,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":1315637,"accession_number":"0001628280-26-045885","cik":1688757,"company_name":"ESTABLISHMENT LABS HOLDINGS INC.","ticker":"ESTA","form_type":"8-K","filed_at":"2026-06-29T12:05:56+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Establishment Labs appoints Taylor Harris to Board of Directors","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Taylor Harris appointed to Board effective June 24, 2026; will serve on Audit and Nominating & Governance Committees.","25+ years experience in healthcare, medtech, and life sciences; most recently CEO of Cutera and CFO of MyoKardia (acquired by BMS for $13.1B).","New director receives initial equity grant of $170,000 under updated non-employee director compensation policy.","Harris's appointment fills a board seat until the 2027 annual meeting; no arrangements or material interests with other parties."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":2113690694.5902975,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":610317,"accession_number":"0001688757-26-000044","cik":1688757,"company_name":"ESTABLISHMENT LABS HOLDINGS INC.","ticker":"ESTA","form_type":"8-K","filed_at":"2026-05-22T20:29:55+00:00","items":["5.07","9.01"],"status":"ready","headline":"Establishment Labs annual meeting results: all directors elected, advisory pay approved, auditor ratified","summary_kind":"llm","event_type":"other","confidence":"high","bullets":["Seven directors elected with votes ranging from 17.3M to 20.0M; broker non-votes 3.1M.","Advisory vote on named executive officer compensation passed with 20.0M for, 30.5K against.","Ratification of CBIZ, CPAs P.C. as independent auditor for FY2026 approved with 22.7M for, 405.7K against.","No other proposals or material items presented at the May 22, 2026 meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.25,"calibrated_materiality_score":0.15,"market_cap_usd":2113690694.5902975,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":94693,"accession_number":"0001688757-26-000038","cik":1688757,"company_name":"ESTABLISHMENT LABS HOLDINGS INC.","ticker":"ESTA","form_type":"8-K","filed_at":"2026-05-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Establishment Labs Q1 revenue $59.9M (+44.7% YoY); raises FY guidance; adj. EBITDA positive for 3rd quarter","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue of $59.9M, up 44.7% YoY; US Motiva sales $19.6M (vs $6.2M Q1 2025).","Gross margin 70.7% (up from 67.2% YoY); operating loss narrowed to $6.5M from $16.9M.","Adjusted EBITDA of $1.2M vs loss of $12.1M YoY; cash balance $68.1M.","FY 2026 revenue guidance raised to $266.5M-$268.5M; minimally invasive revenue seen >$35M.","Expects free cash flow positive in H2 2026; reaffirms positive adjusted EBITDA each quarter."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.45,"consensus_revenue_estimate":null,"consensus_revenue_actual":59877000.0,"consensus_period":"2026-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2113690694.5902975,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":94692,"accession_number":"0001688757-26-000033","cik":1688757,"company_name":"ESTABLISHMENT LABS HOLDINGS INC.","ticker":"ESTA","form_type":"8-K","filed_at":"2026-04-30T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Establishment Labs enters up to $300M credit facility with Oaktree; repays ~$259M existing debt","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Tranche E Term Loan of $265M drawn April 30, 2026; optional Tranche F up to $35M.","Maturity April 30, 2031; interest rate 8.75% p.a. with PIK option and step-ups.","~$259M used to repay Prior Credit Agreement (April 2022) and transaction costs.","Financial covenants: minimum liquidity $30M and minimum gross sales test; equity cure available.","Existing subsidiaries guarantee obligations; customary covenants on additional debt, liens, M&A."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":2113690694.5902975,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107270,"accession_number":"0001688757-26-000014","cik":1688757,"company_name":"ESTABLISHMENT LABS HOLDINGS INC.","ticker":"ESTA","form_type":"8-K","filed_at":"2026-02-24T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Establishment Labs Q4 rev $64.6M (+45% YoY); guides 2026 rev $264-266M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Full year 2025 revenue $211.1M (+27.2% YoY); Q4 net loss $3.9M vs $18.7M loss a year ago.","Q4 adjusted EBITDA positive $5.5M vs ($13.1M) YoY; cash balance $75.6M at Dec 31, 2025.","Motiva U.S. Q4 revenue $17.3M; full year U.S. revenue $45.6M.","2026 revenue guidance $264-266M (+25-26% YoY); 2027 revenue growth projected at least 25%.","CEO cites Preservé product driving market expansion and expects first positive cash flow quarter in 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.72,"consensus_revenue_estimate":null,"consensus_revenue_actual":211076000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2113690694.5902975,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107269,"accession_number":"0001688757-26-000008","cik":1688757,"company_name":"ESTABLISHMENT LABS HOLDINGS INC.","ticker":"ESTA","form_type":"8-K","filed_at":"2026-01-14T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Presentation at J.P. Morgan conference; no financial updates disclosed","summary_kind":"llm","event_type":"other_material","confidence":"low","bullets":["Furnished presentation materials for J.P. Morgan Healthcare Conference on Jan 14, 2026.","No specific financial data, guidance changes, or operational updates included in filing.","Exhibit 99.1 presentation not appended; cannot extract substantive details."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.1,"calibrated_materiality_score":0.1,"market_cap_usd":2113690694.5902975,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":107268,"accession_number":"0001688757-26-000004","cik":1688757,"company_name":"ESTABLISHMENT LABS HOLDINGS INC.","ticker":"ESTA","form_type":"8-K","filed_at":"2026-01-12T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Establishment Labs expects Q4 revenue $64M-$65M; FY 2025 up 27% YoY","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2025 revenue expected $64.0M-$65.0M, including $17.0M-$17.5M from Motiva US sales.","FY 2025 revenue expected $210.5M-$211.5M, ~27% growth over 2024; Motiva US $45.4M-$45.9M.","Year-end cash ~$75.5M, increase of $4.8M from Q3 2025.","Positive adjusted EBITDA; expects free cash flow positive later in 2026.","Preliminary unaudited results; full FY2025 results on February earnings call."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.72,"consensus_revenue_estimate":null,"consensus_revenue_actual":211076000.0,"consensus_period":"2025-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2113690694.5902975,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123614,"accession_number":"0001628280-25-049261","cik":1688757,"company_name":"ESTABLISHMENT LABS HOLDINGS INC.","ticker":"ESTA","form_type":"8-K","filed_at":"2025-11-05T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Establishment Labs Q3 revenue $53.8M (+33.8% YoY), positive Adj. EBITDA, raises FY guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $53.8M, up 33.8% YoY; US Motiva sales $11.9M.","Gross margin 70.1% vs 63.9% YoY; operating loss narrowed to $4.0M from $13.1M.","Adjusted EBITDA positive $1.2M vs loss of $7.0M in Q3 2024.","FY 2025 revenue guidance raised to >$210M from prior $208-212M.","Cash $70.6M; cash burn improved to $8.5M from $14.9M YoY."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.64,"consensus_revenue_estimate":null,"consensus_revenue_actual":146459000.0,"consensus_period":"2025-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2113690694.5902975,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":123613,"accession_number":"0001688757-25-000062","cik":1688757,"company_name":"ESTABLISHMENT LABS HOLDINGS INC.","ticker":"ESTA","form_type":"8-K","filed_at":"2025-10-03T23:59:59+00:00","items":["1.01","2.03","9.01"],"status":"ready","headline":"Establishment Labs amends credit agreement, draws $25M Tranche D term loans","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Fourth Amendment allows immediate availability of $25M Tranche D Term Loans, waiving revenue milestone.","Minimum liquidity requirement increased from $25M to $30M effective Sept 28, 2025.","Company fully drew $25M Tranche D Term Loans on Sept 29, 2025.","Amendment with Oaktree and other lenders to existing Credit Agreement."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":2113690694.5902975,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":140299,"accession_number":"0001688757-25-000054","cik":1688757,"company_name":"ESTABLISHMENT LABS HOLDINGS INC.","ticker":"ESTA","form_type":"8-K","filed_at":"2025-08-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Establishment Labs Q2 revenue $51.3M (+16% YoY); raises FY2025 guidance to $208-212M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $51.3M, up 16.3% YoY; US Motiva sales $10.3M.","FY2025 revenue guidance raised to $208-212M from $205-210M; US Motiva revenue at least $40M.","Gross margin 68.8% vs 65.6% YoY; adjusted EBITDA loss $8.5M vs $4.1M.","Net loss $16.6M vs $17.2M; cash $54.6M plus $25M credit line.","CEO: on track for positive EBITDA in 2025, cash flow positive in 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.29,"consensus_revenue_estimate":null,"consensus_revenue_actual":92677000.0,"consensus_period":"2025-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":2113690694.5902975,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157951,"accession_number":"0001688757-25-000050","cik":1688757,"company_name":"ESTABLISHMENT LABS HOLDINGS INC.","ticker":"ESTA","form_type":"8-K","filed_at":"2025-06-12T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Motiva USA update: >1,000 surgeons, Q2 sales guide $9.5-10M, reconstruction filing Q4 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Over 1,000 surgeons now offer Motiva implants in the United States.","Q2 2025 Motiva US sales expected $9.5M–$10M (partial quarter).","Company to seek US FDA approval for Motiva reconstruction use in Q4 2025.","Preservé US launch anticipated in first half of 2026."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":2113690694.5902975,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157950,"accession_number":"0001688757-25-000045","cik":1688757,"company_name":"ESTABLISHMENT LABS HOLDINGS INC.","ticker":"ESTA","form_type":"8-K","filed_at":"2025-05-27T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"Shareholders re-elect all director nominees; Bryan Slotkin receives 92% for","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["All four director nominees elected: Chacón Quirós, Custin, Lewin, Schutter each received >21.4M for; Slotkin 19.9M for, 1.7M against.","Advisory vote on executive compensation passed with 21.6M for, 56k against, 4.1M broker non-votes.","Ratification of CBIZ as independent auditor for FY2025 passed with 25.7M for, 38k against.","Meeting held May 23, 2025; all proposals approved with strong majorities."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.15,"calibrated_materiality_score":0.15,"market_cap_usd":2113690694.5902975,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157949,"accession_number":"0001688757-25-000044","cik":1688757,"company_name":"ESTABLISHMENT LABS HOLDINGS INC.","ticker":"ESTA","form_type":"8-K","filed_at":"2025-05-22T23:59:59+00:00","items":["4.01","8.01","9.01"],"status":"ready","headline":"Establishment Labs replaces auditor Marcum with CBIZ after acquisition of attest business","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Marcum resigned May 20, 2025; Audit Committee appointed CBIZ same day for FY 2025.","No disagreements or reportable events other than a previously disclosed material weakness in ITGC for FY 2023.","Marcum's audit reports for FY 2024 and 2023 were unqualified.","Company filed proxy supplement to reflect CBIZ as auditor for ratification vote at May 23 annual meeting."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":2113690694.5902975,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157948,"accession_number":"0001688757-25-000036","cik":1688757,"company_name":"ESTABLISHMENT LABS HOLDINGS INC.","ticker":"ESTA","form_type":"8-K","filed_at":"2025-05-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Establishment Labs Q1 revenue $41.4M, net loss $20.7M; appoints Peter Caldini CEO","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 revenue $41.4M (up from $37.2M YoY); net loss $20.7M vs $16.2M loss in prior year.","Gross margin improved to 67.2% from 65.6%, driven by geographic mix and higher ASPs.","Adjusted EBITDA loss $12.1M; cash $69.2M, down $21.2M from year-end 2024.","FY 2025 revenue guidance reaffirmed at $205-210M (23-26% YoY growth).","Peter Caldini appointed CEO effective May 7, 2025; also launched Preservé platform."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.7,"consensus_revenue_estimate":null,"consensus_revenue_actual":41377000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2113690694.5902975,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157947,"accession_number":"0001688757-25-000034","cik":1688757,"company_name":"ESTABLISHMENT LABS HOLDINGS INC.","ticker":"ESTA","form_type":"8-K","filed_at":"2025-05-07T23:59:59+00:00","items":["5.02","7.01","9.01"],"status":"ready","headline":"Establishment Labs appoints Peter Caldini as permanent CEO, effective May 7, 2025","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Caldini had served as interim CEO since March 1, 2025, following founder Juan José Chacón-Quirós's retirement.","He will also fill the Class II director vacancy created by the death of director Dennis Condon, term expiring at 2026 AGM.","No change in Caldini's compensation; he will not receive extra director compensation as an employee.","Chairman Nick Lewin emphasized execution goals: turning EBITDA positive in 2025 and cash flow positive in 2026.","Founder Chacón-Quirós remains on the board and will continue supporting R&D and product adoption."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":2113690694.5902975,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":157946,"accession_number":"0001688757-25-000022","cik":1688757,"company_name":"ESTABLISHMENT LABS HOLDINGS INC.","ticker":"ESTA","form_type":"8-K","filed_at":"2025-04-10T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Establishment Labs reports preliminary Q1 revenue $41.4M, reiterates 2025 guidance $205-210M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Preliminary Q1 2025 revenue ~$41.4M, including ~$6.2M US Motiva sales.","Reaffirms 2025 revenue guidance $205-210M; expects EBITDA positive in 2025 and cash flow positive in 2026.","Tariffs impact less than 50 bps gross margin; no disruption from recent events.","Average daily orders in March surpassed 100; US launch accelerating.","Investor Day scheduled for June 12, 2025 in NYC; live webcast available."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.7,"consensus_revenue_estimate":null,"consensus_revenue_actual":41377000.0,"consensus_period":"2025-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":2113690694.5902975,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":176336,"accession_number":"0001688757-25-000011","cik":1688757,"company_name":"ESTABLISHMENT LABS HOLDINGS INC.","ticker":"ESTA","form_type":"8-K","filed_at":"2025-02-26T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Establishment Labs Q4 revenue $44.5M; reaffirms 2025 guidance of $205-210M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue $44.5M (+41% YoY); gross margin 68.5% (up from 65.2%).","Net loss from operations $18.7M (improved from $22.1M); adj EBITDA loss $13.1M (from $17.4M).","U.S. Motiva launch: Q4 revenue $3.3M; Q1 2025 U.S. revenue expected ~$5.5M.","Cash $90.3M; additional $25M credit facility available, total accessible ~$115M.","2025 revenue guidance reaffirmed $205-210M; targeting first positive EBITDA quarter."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.0,"consensus_revenue_estimate":null,"consensus_revenue_actual":166025000.0,"consensus_period":"2024-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2113690694.5902975,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":176335,"accession_number":"0001688757-25-000008","cik":1688757,"company_name":"ESTABLISHMENT LABS HOLDINGS INC.","ticker":"ESTA","form_type":"8-K","filed_at":"2025-01-16T23:59:59+00:00","items":["7.01"],"status":"ready","headline":"Establishment Labs guides 2025 revenue $205M-$210M, positive adjusted EBITDA in 2025","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["2025 revenue guidance of $205M-$210M ($170M-$175M international, $35M US).","Expects positive adjusted EBITDA in 2025.","Expects positive cash flow in 2026.","Guidance provided at J.P. Morgan Healthcare Conference on Jan 15, 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":2113690694.5902975,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":176334,"accession_number":"0001688757-25-000003","cik":1688757,"company_name":"ESTABLISHMENT LABS HOLDINGS INC.","ticker":"ESTA","form_type":"8-K","filed_at":"2025-01-13T23:59:59+00:00","items":["2.02","5.02","7.01","9.01"],"status":"ready","headline":"Founder CEO Chacón-Quirós to retire March 1; 2024 revenue guidance $166M-$166.5M","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["CEO Juan José Chacón-Quirós retires effective March 1, 2025; stays on board and as advisor.","President Peter Caldini becomes Interim CEO; previously CEO of Acreage Holdings and Pfizer executive.","Preliminary 2024 revenue expected $166M-$166.5M; Q4 2024 revenue $44.5M-$45.0M.","Q4 includes approx. $3.2M from Motiva sales in the United States.","Revenue in line with prior guidance; no full earnings metrics provided."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":2113690694.5902975,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":193202,"accession_number":"0001688757-24-000097","cik":1688757,"company_name":"ESTABLISHMENT LABS HOLDINGS INC.","ticker":"ESTA","form_type":"8-K","filed_at":"2024-11-12T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Establishment Labs extends Tranche D loan commitment to Dec 2025 and raises ~$49.8M in equity","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Amended credit agreement: Tranche D term loan commitment termination date extended to Dec 31, 2025 from June 30, 2025.","New milestone for Tranche D availability: trailing 12-month gross sales of $195M total and $30M in US for Motiva/Flora.","Registered direct offering of 765,696 common shares at $45.71/share plus pre-funded warrants for 328,154 common shares at $45.709.","Net proceeds ~$49.8M for general corporate purposes such as sales/marketing, R&D, working capital.","Additional 10% of shares/warrants issuable if average closing price does not exceed $45.71 in Jan–Aug 2025."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":2113690694.5902975,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":193201,"accession_number":"0001688757-24-000091","cik":1688757,"company_name":"ESTABLISHMENT LABS HOLDINGS INC.","ticker":"ESTA","form_type":"8-K","filed_at":"2024-11-07T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Establishment Labs announces $50M registered direct offering and FY2024 revenue guidance of $165-168M","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Offering of 765,696 common shares at $45.71/share and pre-funded warrants for 328,161 shares; total gross proceeds ~$50M.","Additional 76,569 shares and 32,815 warrant shares issuable if average closing price ≤$45.71 between Jan-Aug 2025.","FY2024 revenue expected $165-168M; FY2025 non-U.S. revenue mid-single digit growth; U.S. revenue >$35M.","Credit agreement amended: Tranche D commitment termination extended to Dec 31, 2025; milestone set at $195M trailing 12-month gross sales including $30M U.S. for Motiva.","Net proceeds to be used for sales/marketing, R&D, working capital, and capex."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2113690694.5902975,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":193200,"accession_number":"0001688757-24-000088","cik":1688757,"company_name":"ESTABLISHMENT LABS HOLDINGS INC.","ticker":"ESTA","form_type":"8-K","filed_at":"2024-11-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Establishment Labs Q3 revenue $40.2M, cuts 2024 guidance to $165-168M, raises $50M in direct offering","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 revenue $40.2M vs $38.5M YoY; net loss $16.7M vs $29.3M loss YoY; adjusted EBITDA loss $7.0M vs $16.3M loss.","2024 revenue guidance reduced to $165-168M from prior $174-184M due to FDA delay and Brazil weakness.","Cash $39.7M at Sep 30; pro forma $114M after $25M Oaktree draw and $50M registered direct offering (5% discount).","FDA approved Motiva Implants Sep 26; U.S. launch added 250+ accounts in first three weeks; expects >$35M U.S. revenue in 2025.","Oaktree facility amended: $25M Tranche D available through Dec 31, 2025 subject to revenue milestones."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.8,"consensus_revenue_estimate":null,"consensus_revenue_actual":121511000.0,"consensus_period":"2024-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":2113690694.5902975,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":209575,"accession_number":"0001688757-24-000084","cik":1688757,"company_name":"ESTABLISHMENT LABS HOLDINGS INC.","ticker":"ESTA","form_type":"8-K","filed_at":"2024-09-26T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"FDA approves Motiva SmoothSilk implants for breast augmentation; first new PMA since 2013","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA approval for Motiva SmoothSilk Ergonomix and Round implants in primary and revision breast augmentation.","Three-year clinical trial data: capsular contracture 0.5%, rupture 0.6%, infection 0.9% in primary augmentation cohort.","First new breast implant PMA approved by FDA since 2013; nearly 4 million Motiva devices already delivered in 85+ countries.","CEO Juan José Chacón-Quirós calls approval transformative for U.S. breast aesthetics, citing differentiated technology.","Study conducted at 32 U.S. and 3 European centers; patient compliance at 92.4% at 3-year endpoint."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.85,"calibrated_materiality_score":0.85,"market_cap_usd":2113690694.5902975,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":209574,"accession_number":"0001688757-24-000079","cik":1688757,"company_name":"ESTABLISHMENT LABS HOLDINGS INC.","ticker":"ESTA","form_type":"8-K","filed_at":"2024-08-26T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Appoints Fillipo 'Peter' Caldini as President; base salary $415K, $1M equity grant","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Appointed Fillipo 'Peter' Caldini as President effective August 20, 2024, reporting to CEO.","Base salary $415K; annual bonus target 50% of base; annual equity award target 100% of base.","New hire equity grant: $600K in options and $400K in RSUs, vesting over 4 years.","Previously CEO of Acreage Holdings and regional president at Pfizer Consumer Healthcare; held roles at Bayer.","Severance: 9 months salary on non-CIC termination; 12 months salary plus full bonus acceleration on CIC termination."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":2113690694.5902975,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":209573,"accession_number":"0001688757-24-000071","cik":1688757,"company_name":"ESTABLISHMENT LABS HOLDINGS INC.","ticker":"ESTA","form_type":"8-K","filed_at":"2024-08-06T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Establishment Labs Q2 revenue $44.1M, loss narrows; FDA PMA inspection completed","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 revenue $44.1M vs $48.6M YoY; gross margin improved to 65.6% from 62.3%.","Operating loss $9.3M vs $13.7M loss YoY; adjusted EBITDA loss $4.3M vs $9.3M.","Net loss $17.2M; cash $54.6M, up $14.6M from Dec 2023.","FY2024 revenue guidance reaffirmed $174M-$184M (+5-11% YoY).","FDA completed PMA preapproval inspection July 26; Motiva Implants US approval expected soon."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.21,"consensus_revenue_estimate":null,"consensus_revenue_actual":81284000.0,"consensus_period":"2024-Q2","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":2113690694.5902975,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":209572,"accession_number":"0001688757-24-000067","cik":1688757,"company_name":"ESTABLISHMENT LABS HOLDINGS INC.","ticker":"ESTA","form_type":"8-K","filed_at":"2024-07-16T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"FDA PMA preapproval inspection of Establishment Labs' Motiva Implant facility rescheduled to July 22","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA will begin PMA preapproval inspection of Motiva Implants manufacturing facility on July 22, 2024.","Inspection was previously scheduled for the first week of July 2024.","Rescheduling is a procedural update; no new findings or delays beyond the date change."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":2113690694.5902975,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":227675,"accession_number":"0001688757-24-000065","cik":1688757,"company_name":"ESTABLISHMENT LABS HOLDINGS INC.","ticker":"ESTA","form_type":"8-K","filed_at":"2024-06-05T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"FDA deems Establishment Labs' Motiva Implants PMA approvable pending facility inspection","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA CDRH completed PMA review for Motiva Implants; says PMA is approvable subject to acceptable manufacturing facility inspection.","FDA inspection of manufacturing facilities rescheduled from prior dates to occur within next 30 days.","Announced June 5, 2024 at Jefferies Global Healthcare Conference."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":2113690694.5902975,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":227674,"accession_number":"0001688757-24-000063","cik":1688757,"company_name":"ESTABLISHMENT LABS HOLDINGS INC.","ticker":"ESTA","form_type":"8-K","filed_at":"2024-05-28T23:59:59+00:00","items":["5.07","9.01"],"status":"ready","headline":"Establishment Labs shareholders elect directors, approve say-on-pay, ratify auditor","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Ann Custin received 18,049,023 votes for, 1,659,450 against; Bryan Slotkin 18,175,945 for, 1,532,799 against.","Advisory vote on named executive officer compensation passed: 17,999,791 for, 1,708,025 against.","Ratification of Marcum LLP as auditor for FY2024: 20,177,610 for, 2,775,431 against.","Broker non-votes of 3,244,356 on director elections and say-on-pay proposals."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.15,"market_cap_usd":2113690694.5902975,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":227673,"accession_number":"0001688757-24-000056","cik":1688757,"company_name":"ESTABLISHMENT LABS HOLDINGS INC.","ticker":"ESTA","form_type":"8-K","filed_at":"2024-05-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Establishment Labs reports Q1 revenue down 20% YoY; narrows operating loss sequentially; reaffirms 2024 guidance","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q1 2024 revenue $37.2M (down 20% YoY from $46.5M); net loss $16.2M vs $11.9M loss in Q1 2023.","Adjusted EBITDA loss improved to $3.7M from $17.3M in Q4 2023; operating loss $8.8M vs $22.1M in Q4 2023.","Cash balance $73.0M, up $32.9M from Dec 31, 2023 due to private placement; 2024 revenue guidance reaffirmed at $174M-$184M.","Company presented 4-year Motiva US IDE study data with low capsular contracture/rupture rates; expects FDA approval in 2024.","Launched Motiva implants in China and Flora tissue expander in US; cost reduction initiatives lowered SG&A and R&D expenses."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.58,"consensus_revenue_estimate":null,"consensus_revenue_actual":37167000.0,"consensus_period":"2024-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":2113690694.5902975,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":227672,"accession_number":"0001688757-24-000042","cik":1688757,"company_name":"ESTABLISHMENT LABS HOLDINGS INC.","ticker":"ESTA","form_type":"8-K","filed_at":"2024-04-02T23:59:59+00:00","items":["8.01"],"status":"ready","headline":"FDA schedules PMA preapproval inspection of Establishment Labs' Motiva Implants facility in Q2 2024","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["FDA schedules PMA preapproval inspection of Motiva Implants manufacturing facility for Q2 2024.","Inspection is a required step in the premarket approval (PMA) process for U.S. market entry.","Announcement made on April 2, 2024 during J.P. Morgan MedTech CEO Conference."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":2113690694.5902975,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":246473,"accession_number":"0001688757-24-000022","cik":1688757,"company_name":"ESTABLISHMENT LABS HOLDINGS INC.","ticker":"ESTA","form_type":"8-K","filed_at":"2024-02-28T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Establishment Labs Q4 revenue falls 28% YoY to $31.6M; guides 2024 rev up 5-11% to $174-184M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 revenue $31.6M vs $43.8M prior year; net loss from operations $22.1M vs $13.2M.","Adjusted EBITDA loss of $17.3M in Q4 vs $8.9M loss a year ago.","2024 revenue guidance $174-184M (+5-11%); excludes US Motiva Implants revenue expected in 2024.","Proforma cash $90M after Jan $50M private placement; Oaktree facility amended for up to $50M post-FDA approval.","Launched Motiva Implants in China; first US commercial procedure with Motiva Flora tissue expander."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.07,"consensus_revenue_estimate":null,"consensus_revenue_actual":165151000.0,"consensus_period":"2023-FY","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2113690694.5902975,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":246472,"accession_number":"0001688757-24-000015","cik":1688757,"company_name":"ESTABLISHMENT LABS HOLDINGS INC.","ticker":"ESTA","form_type":"8-K","filed_at":"2024-02-22T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Establishment Labs amends credit agreement; extends Tranche C/D deadlines, raises rate to 10%","summary_kind":"llm","event_type":"debt","confidence":"high","bullets":["Commitment termination dates extended: Tranche C to Dec 31, 2024 (from Mar 31, 2024); Tranche D to Jun 30, 2025 (from Dec 31, 2024).","Interest rate on Tranche C and D loans increased from 9.0% to 10.0% per annum.","Tranche C funding now conditional on FDA approval of Motiva Implants for U.S. augmentation; $185M sales alternative removed.","Tranche D milestone reduced to $195M trailing sales (from $225M); funding of Tranche C is a prerequisite.","Prepayment premium revised: make-whole plus 4% for any prepayment within one year after advance."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":2113690694.5902975,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":246471,"accession_number":"0001688757-24-000011","cik":1688757,"company_name":"ESTABLISHMENT LABS HOLDINGS INC.","ticker":"ESTA","form_type":"8-K","filed_at":"2024-01-31T23:59:59+00:00","items":["8.01","9.01"],"status":"ready","headline":"Establishment Labs files prospectus supplement for resale of up to 2M common shares by selling shareholders","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Prospectus supplement covers resale of up to 2,000,000 common shares, including shares issuable upon exercise of pre-funded warrants.","Selling shareholders include holders from Jan 9, 2024 securities purchase agreement; 1,101,565 shares and 898,435 warrant shares.","Registration statement on Form S-3 filed earlier; this is a takedown for existing shareholders' resale."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.3,"calibrated_materiality_score":0.3,"market_cap_usd":2113690694.5902975,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":246470,"accession_number":"0001688757-24-000005","cik":1688757,"company_name":"ESTABLISHMENT LABS HOLDINGS INC.","ticker":"ESTA","form_type":"8-K","filed_at":"2024-01-09T23:59:59+00:00","items":["1.01","2.02","3.02","7.01","9.01"],"status":"ready","headline":"Establishment Labs raises $50M via private placement; Q4 rev. $31.4-$31.8M in-line","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Gross proceeds of $50M from sale of 2M common shares/pre-funded warrants at $25.00 per share.","Preliminary Q4 2023 revenue $31.4M-$31.8M; FY 2023 revenue $165.0M-$165.4M.","Year-end 2023 cash ~$39.1M, down $12.9M from Q3; targeting EBITDA positive in 2024 and cash positive in 2025.","Private placement led by Nantahala Capital and RTW; proceeds for working capital and corporate purposes."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2113690694.5902975,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":263892,"accession_number":"0001688757-23-000084","cik":1688757,"company_name":"ESTABLISHMENT LABS HOLDINGS INC.","ticker":"ESTA","form_type":"8-K","filed_at":"2023-12-14T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"COO Paul D. Rodio departs; CEO assumes operating officer duties","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Paul D. Rodio, COO, departed Establishment Labs on Dec 8, 2023.","CEO Juan José Chacón Quirós assumed Rodio's management responsibilities as principal operating officer.","Rodio eligible for severance benefits per employment agreement upon signing release.","No permanent replacement named for COO role."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"negative","materiality_score":0.6,"calibrated_materiality_score":0.6,"market_cap_usd":2113690694.5902975,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":263891,"accession_number":"0001688757-23-000079","cik":1688757,"company_name":"ESTABLISHMENT LABS HOLDINGS INC.","ticker":"ESTA","form_type":"8-K","filed_at":"2023-11-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Establishment Labs Q3 revenue $38.5M (+0.8% YoY); net loss widens to $29.3M; cuts 2023 guidance to ~$165M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $38.5M (+0.8% YoY); net loss $29.3M vs $18.6M; operating loss $21.0M vs $10.5M.","2023 revenue guidance lowered to ~$165M (up 2% over 2022); China approval removed from forecasts.","Cash $52.2M at Sep 30; cash burn $14.2M since Dec 31, partially offset by Apr follow-on offering.","FDA clearance of Motiva Flora SmoothSilk Tissue Expander on Oct 13; Mia Femtech 2-year data shows no capsular contracture.","Reaffirms $500M revenue target for 2026 despite near-term demand softness."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.28,"consensus_revenue_estimate":null,"consensus_revenue_actual":133591000.0,"consensus_period":"2023-Q3","consensus_source":"xbrl_only","sentiment":"negative","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2113690694.5902975,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":281113,"accession_number":"0001688757-23-000073","cik":1688757,"company_name":"ESTABLISHMENT LABS HOLDINGS INC.","ticker":"ESTA","form_type":"8-K","filed_at":"2023-08-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Establishment Labs reports record Q2 revenue of $48.6M, up 18% YoY; net loss narrows to $16.7M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q2 2023 revenue of $48.6M (+18% YoY) sets new quarterly record; gross margin 62.3% vs 66.7% a year ago.","Net loss of $16.7M improved from $37.1M in Q2 2022; operating loss widened to $13.7M from $10.4M.","Cash balance $90.2M, boosted by April 27 follow-on offering of 1.265M shares.","FY 2023 revenue guidance maintained at $200-210M, representing 24-30% annual growth.","Mia Femtech has 14 clinic partners; U.S. PMA progressing; new Sulàyöm campus opened July 19."],"consensus_eps_estimate":null,"consensus_eps_actual":-1.14,"consensus_revenue_estimate":null,"consensus_revenue_actual":95085000.0,"consensus_period":"2023-Q2","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.75,"calibrated_materiality_score":0.75,"market_cap_usd":2113690694.5902975,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":299860,"accession_number":"0001688757-23-000067","cik":1688757,"company_name":"ESTABLISHMENT LABS HOLDINGS INC.","ticker":"ESTA","form_type":"8-K","filed_at":"2023-05-31T23:59:59+00:00","items":["5.03","5.07","9.01"],"status":"ready","headline":"Establishment Labs shareholders approve board declassification and remove supermajority votes","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Board declassification over three years: directors elected from 2024 onward serve one-year terms, complete by 2026.","Supermajority voting requirements eliminated for charter amendments and director removal; simple majority now applies.","Class II directors Dennis Condon (14,788,698 for) and Leslie Gillin (17,071,800 for) elected to serve until 2026.","Advisory say-on-pay approved (17,132,043 for, 515,786 against); ratification of Marcum LLP as auditor (19,179,436 for).","All five shareholder proposals passed, including charter amendments filed with BVI corporate registry."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.35,"calibrated_materiality_score":0.35,"market_cap_usd":2113690694.5902975,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":299859,"accession_number":"0001688757-23-000053","cik":1688757,"company_name":"ESTABLISHMENT LABS HOLDINGS INC.","ticker":"ESTA","form_type":"8-K","filed_at":"2023-05-08T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Establishment Labs Q1 revenue $46.5M (+21% YoY), net loss widens to $11.9M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue $46.5M, record quarterly, up 21.0% YoY; currency-adjusted growth 22.9%.","Operating loss $8.2M vs $5.6M loss YoY; net loss $11.9M vs $5.9M loss YoY.","Cash $42.8M; completed follow-on offering April 27 with $90.4M gross proceeds.","2023 revenue guidance reaffirmed $200-210M, representing 24-30% YoY increase.","Mia Femtech launched in Japan April 10; Motiva IDE 3-year results presented."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.48,"consensus_revenue_estimate":null,"consensus_revenue_actual":46524000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"neutral","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":2113690694.5902975,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":299858,"accession_number":"0001104659-23-051312","cik":1688757,"company_name":"ESTABLISHMENT LABS HOLDINGS INC.","ticker":"ESTA","form_type":"8-K","filed_at":"2023-04-27T23:59:59+00:00","items":["1.01","9.01"],"status":"ready","headline":"Establishment Labs raises ~$84.1M in public offering of 1.1M shares at $71.50/share","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["Underwriting agreement for 1,100,000 common shares at $67.21 per share to underwriters; public price $71.50.","Underwriters exercised 30-day option to purchase an additional 165,000 shares.","Net proceeds to company approximately $84.1 million after underwriting discounts and expenses.","Offering closed on April 27, 2023; all shares sold by the company."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":2113690694.5902975,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":299857,"accession_number":"0001104659-23-049001","cik":1688757,"company_name":"ESTABLISHMENT LABS HOLDINGS INC.","ticker":"ESTA","form_type":"8-K","filed_at":"2023-04-24T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Establishment Labs Q1 2023 preliminary revenue ~$46.5M, up 21% YoY","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Revenue expected ~$46.5M, compared to $38.5M in Q1 2022, a 21% YoY increase.","Cash balance ~$42.8M as of March 31, 2023; credit facility debt ~$184.0M (principal and interest).","Results are preliminary and unaudited, subject to finalization and audit."],"consensus_eps_estimate":null,"consensus_eps_actual":-0.48,"consensus_revenue_estimate":null,"consensus_revenue_actual":46524000.0,"consensus_period":"2023-Q1","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":2113690694.5902975,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":299856,"accession_number":"0001104659-23-047762","cik":1688757,"company_name":"ESTABLISHMENT LABS HOLDINGS INC.","ticker":"ESTA","form_type":"8-K","filed_at":"2023-04-20T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Establishment Labs reports 3-year Motiva IDE study data; capsular contracture rate 0.5%","summary_kind":"llm","event_type":"other_material","confidence":"high","bullets":["3-year follow-up on 451 primary augmentation patients; compliance 92.4%.","Kaplan-Meier risk rates: capsular contracture 0.5%, rupture 0.6%, breast pain 0.7%, infection 0.9%.","Any reoperation 6.1%, any complication 8.4% at 3 years.","Data submitted to FDA as part of final PMA module; device not yet approved in US.","Results consistent from year 2 to year 3 with no increase in capsular contracture or rupture."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":2113690694.5902975,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":319948,"accession_number":"0001688757-23-000014","cik":1688757,"company_name":"ESTABLISHMENT LABS HOLDINGS INC.","ticker":"ESTA","form_type":"8-K","filed_at":"2023-02-27T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Establishment Labs submits final PMA module for Motiva to FDA; Q4 revenue $43.8M, up 24% YoY; guides 2023 $200-210M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Submitted fourth and final module to U.S. FDA for premarket approval of Motiva Implants in the U.S.","Q4 2022 revenue $43.8M, up 24.1% YoY; operating loss $13.6M vs $14.2M loss in prior year.","2023 revenue guidance $200M-$210M, representing 24%-30% growth over 2022.","Cash balance $66.4M as of Dec 31, 2022; increased $12.9M from prior year.","Mia Femtech commercialization on track; China approval expected H1 2023."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.08,"consensus_revenue_estimate":null,"consensus_revenue_actual":161700000.0,"consensus_period":"2022-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.8,"calibrated_materiality_score":0.8,"market_cap_usd":2113690694.5902975,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":319947,"accession_number":"0001688757-23-000008","cik":1688757,"company_name":"ESTABLISHMENT LABS HOLDINGS INC.","ticker":"ESTA","form_type":"8-K","filed_at":"2023-01-11T23:59:59+00:00","items":["7.01","9.01"],"status":"ready","headline":"Estab. Labs ready to submit PMA Module 4 for Motiva implants in Q1 2023; targets $500M revenue by FY2026","summary_kind":"llm","event_type":"regulatory","confidence":"high","bullets":["Notified FDA it is ready to submit Module 4 of pre-market approval for Motiva Implants in the U.S.","Expects to file Module 4 during Q1 2023, working with FDA on optimal timing.","CEO to present at 41st J.P. Morgan Healthcare Conference on January 12, 2023.","Company targets $500 million in annual revenue for fiscal year 2026.","Presentation materials furnished as Exhibit 99.1; forward-looking statements noted."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"positive","materiality_score":0.72,"calibrated_materiality_score":0.72,"market_cap_usd":2113690694.5902975,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":319946,"accession_number":"0001688757-23-000005","cik":1688757,"company_name":"ESTABLISHMENT LABS HOLDINGS INC.","ticker":"ESTA","form_type":"8-K","filed_at":"2023-01-09T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Establishment Labs Q4 revenue $43.3-44.3M (+23-25% YoY); FY22 revenue $161.2-162.2M (+27-28% YoY)","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q4 2022 preliminary revenue $43.3-44.3M, up 23-25% YoY (27-29% constant currency).","FY 2022 revenue $161.2-162.2M, up 27-28% YoY (31-32% constant currency).","CEO cites record quarterly and annual revenue, expects Motiva and Mia Femtech catalysts in 2023.","Preliminary unaudited figures subject to change upon audit."],"consensus_eps_estimate":null,"consensus_eps_actual":-3.08,"consensus_revenue_estimate":null,"consensus_revenue_actual":161700000.0,"consensus_period":"2022-FY","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.65,"calibrated_materiality_score":0.65,"market_cap_usd":2113690694.5902975,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":338129,"accession_number":"0001688757-22-000108","cik":1688757,"company_name":"ESTABLISHMENT LABS HOLDINGS INC.","ticker":"ESTA","form_type":"8-K","filed_at":"2022-12-02T23:59:59+00:00","items":["5.02","9.01"],"status":"ready","headline":"Establishment Labs appoints Paul D. Rodio as COO, effective Dec 1, 2022","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Appointed Paul D. Rodio as COO effective Dec 1, 2022; prior roles at Cardinal Health, Medtronic, and Covidien.","Base salary of $375,000 annually; target annual bonus up to 50% of base salary.","New hire stock option grant to purchase 50,000 common shares, vesting over 4 years (1/4 per year).","Eligible for annual equity awards beginning 2024 with grant date fair value ~150% of base salary.","Severance: 9 months base salary (non-CIC) or 12 months base salary (CIC), plus bonus and health benefits."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"market_cap_usd":2113690694.5902975,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":338128,"accession_number":"0001688757-22-000098","cik":1688757,"company_name":"ESTABLISHMENT LABS HOLDINGS INC.","ticker":"ESTA","form_type":"8-K","filed_at":"2022-11-07T23:59:59+00:00","items":["2.02","9.01"],"status":"ready","headline":"Establishment Labs Q3 revenue $38.2M (+31.7% YoY); tightens 2022 guidance to $158-162M","summary_kind":"llm","event_type":"earnings","confidence":"high","bullets":["Q3 revenue $38.2M, up 31.7% YoY (37.7% constant currency); net loss $10.5M vs $9.0M in Q3 2021.","Gross margin improved to 68.1% from 67.6%; operating expenses rose 27.5% to $36.6M.","2022 revenue guidance tightened to $158-162M from $155-165M; constant-currency growth 30-33% YoY.","Cash balance $65.3M as of Sep 30; expects Mia Femtech launch and China approval in 1H 2023.","Plans to submit Motiva Implants for U.S. FDA approval in Q4 2022; all U.S. IDE trial cohorts enrolled."],"consensus_eps_estimate":null,"consensus_eps_actual":-2.53,"consensus_revenue_estimate":null,"consensus_revenue_actual":117887000.0,"consensus_period":"2022-Q3","consensus_source":"xbrl_only","sentiment":"positive","materiality_score":0.7,"calibrated_materiality_score":0.7,"market_cap_usd":2113690694.5902975,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":355497,"accession_number":"0001688757-22-000091","cik":1688757,"company_name":"ESTABLISHMENT LABS HOLDINGS INC.","ticker":"ESTA","form_type":"8-K","filed_at":"2022-09-02T23:59:59+00:00","items":["5.02"],"status":"ready","headline":"Establishment Labs extends option exercise period for departing Head of Global Operations","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Pratip Dastidar departed as Head of Global Operations as of Aug 19, 2022, previously announced.","Company extended the exercise period for Dastidar's vested stock options until September 1, 2023.","No additional severance changes from the prior 8-K filed on August 19, 2022."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.2,"calibrated_materiality_score":0.2,"market_cap_usd":2113690694.5902975,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null},{"id":355496,"accession_number":"0001688757-22-000089","cik":1688757,"company_name":"ESTABLISHMENT LABS HOLDINGS INC.","ticker":"ESTA","form_type":"8-K","filed_at":"2022-08-19T23:59:59+00:00","items":["5.02","8.01"],"status":"ready","headline":"Establishment Labs loses Head of Global Operations; appoints new GC & CCO","summary_kind":"llm","event_type":"leadership","confidence":"high","bullets":["Pratip Dastidar, Head of Global Operations, departs Aug 19, 2022; eligible for severance if he signs general release.","CEO Juan José Chacón Quirós will assume Dastidar's operating officer responsibilities until a replacement is named.","S. Ross Mansbach appointed General Counsel and Chief Compliance Officer, effective Aug 29, 2022; previously at Avanos Medical and Kimberly-Clark."],"consensus_eps_estimate":null,"consensus_eps_actual":null,"consensus_revenue_estimate":null,"consensus_revenue_actual":null,"consensus_period":null,"consensus_source":null,"sentiment":"neutral","materiality_score":0.5,"calibrated_materiality_score":0.5,"market_cap_usd":2113690694.5902975,"market_cap_bucket":"not_microcap","market_cap_source":"finnhub_profile2","market_cap_as_of_date":"2026-05-28","daily_digest_date":null,"daily_digest_url":null,"daily_digest_rank":null}],"next_cursor":"2022-08-19T23:59:59+00:00|355496"}